CoChat
Sign Up
Cited by 435Gut microbiota and healthParkinson's Disease Mechanisms and TreatmentsGastrointestinal motility and disorders

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease

Open access
Aho, Velma T. E., Houser, Madelyn C., Pereira, Pedro A. B., Chang, Jianjun, Rudi, Knut, Paulin, Lars, Hertzberg, Vicki, Auvinen, Petri, Tansey, Malú G., Scheperjans, Filip·2021·Molecular Neurodegeneration
DOI 10.1186/s13024-021-00427-6PMC PMC7869249

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

Background: Previous studies have reported that gut microbiota, permeability, short-chain fatty acids (SCFAs), and inflammation are altered in Parkinson’s disease (PD), but how these factors are linked and how they contribute to disease processes and symptoms remains uncertain. This study sought to compare and identify associations among these factors in PD patients and controls to elucidate their interrelations and links to clinical manifestations of PD. Methods: Stool and plasma samples and clinical data were collected from 55 PD patients and 56 controls. Levels of stool SCFAs and stool and plasma inflammatory and permeability markers were compared between patients and controls and related to one another and to the gut microbiota. Results: Calprotectin was increased and SCFAs decreased in stool in PD in a sex-dependent manner. Inflammatory markers in plasma and stool were neither intercorrelated nor strongly associated with SCFA levels. Age at PD onset was positively correlated with SCFAs and negatively correlated with CXCL8 and IL-1β in stool. Fecal zonulin correlated positively with fecal NGAL and negatively with PD motor and non-motor symptoms. Microbiota diversity and composition were linked to levels of SCFAs, inflammatory factors, and zonulin in stool. Certain relationships differed between patients and controls and by sex. Conclusions: Intestinal inflammatory responses and reductions in fecal SCFAs occur in PD, are related to the microbiota and to disease onset, and are not reflected in plasma inflammatory profiles. Some of these relationships are distinct in PD and are sex-dependent. This study revealed potential alterations in microbiota-host interactions and links between earlier PD onset and intestinal inflammatory responses and reduced SCFA levels, highlighting candidate molecules and pathways which may contribute to PD pathogenesis and clinical presentation and which warrant further investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13024-021-00427-6

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Differences in analyte levels in PD by sex. Levels of stool butyric acid (p=0.101 female, p=0.003 male) and calprotectin (p=0.019 female, p=0.489 male) and plasma CXCL8 (p=0.017 female, p=0.145 male) in male and female PD patients (n=26 female, 29 male) and control subjects (n=29 female, 27 male) compared by Wilcoxon rank sum test
Fig. 1 Differences in analyte levels in PD by sex. Levels of stool butyric acid (p=0.101 female, p=0.003 male) and calprotectin (p=0.019 female, p=0.489 male) and plasma CXCL8 (p=0.017 female, p=0.145 male) in male and female PD patients (n=26 female, 29 male) and control subjects (n=29 female, 27 male) compared by Wilcoxon rank sum testCC BY · PubMed Central
Fig. 2 Correlations among SCFAs and inflammatory and permeability markers. Pearson correlations in a full data, b Control subjects (n=56), and c PD patients (n=55)
Fig. 2 Correlations among SCFAs and inflammatory and permeability markers. Pearson correlations in a full data, b Control subjects (n=56), and c PD patients (n=55)CC BY · PubMed Central
Fig. 3 Correlations of SCFAs, immune markers, and clinical variables. Pearson correlations of a SCFAs, and immune markers in b plasma and c stool with clinical variables in full data and in only control subjects (n=56) or PD patients (n=55)
Fig. 3 Correlations of SCFAs, immune markers, and clinical variables. Pearson correlations of a SCFAs, and immune markers in b plasma and c stool with clinical variables in full data and in only control subjects (n=56) or PD patients (n=55)CC BY · PubMed Central
Fig. 4 Correlations of alpha diversity for SCFAs and inflammatory and permeability markers. Pearson correlations with Shannon and inverse Simpson diversity indices, n=56 controls, n=55 PD patients; p-value is marked as follows: ***: p ≤ 0.001 / **: p ≤ 0.01 / *: p ≤ 0.05 / .: 0.1 > p > 0.05
Fig. 4 Correlations of alpha diversity for SCFAs and inflammatory and permeability markers. Pearson correlations with Shannon and inverse Simpson diversity indices, n=56 controls, n=55 PD patients; p-value is marked as follows: ***: p ≤ 0.001 / **: p ≤ 0.01 / *: p ≤ 0.05 / .: 0.1 > p > 0.05CC BY · PubMed Central
Fig. 5 Linear modeling for alpha diversity showing effects of PD/control status and sex. a Stool calprotectin and inverse Simpson index and b propionic acid and Shannon index for male and female PD patients (n=26 female, 29 male) and control subjects (n=29 female, 27 male)
Fig. 5 Linear modeling for alpha diversity showing effects of PD/control status and sex. a Stool calprotectin and inverse Simpson index and b propionic acid and Shannon index for male and female PD patients (n=26 female, 29 male) and control subjects (n=29 female, 27 male)CC BY · PubMed Central
Fig. 6 Butyric acid, NGAL, and zonulin levels by enterotype among PD patients and control subjects. Levels of butyric acid (p=0.013 for PD patients), stool NGAL (p=0.002 for control subjects), and stool zonulin (p< 0.001 for control subjects) compared across enterotypes by Kruskal-Wallis test. Asterisks indicate results of pairwise Wilcoxon rank sum post-hoc tests (Bacteroides – 8 control, 8 PD; Firmicutes – 25 control, 35 PD; Prevotella – 22 control, 10 PD) with ***: p ≤ 0.001 / **: p ≤ 0.01 / *: p ≤ 0.05
Fig. 6 Butyric acid, NGAL, and zonulin levels by enterotype among PD patients and control subjects. Levels of butyric acid (p=0.013 for PD patients), stool NGAL (p=0.002 for control subjects), and stool zonulin (p< 0.001 for control subjects) compared across enterotypes by Kruskal-Wallis test. Asterisks indicate results of pairwise Wilcoxon rank sum post-hoc tests (Bacteroides – 8 control, 8 PD; Firmicutes – 25 control, 35 PD; Prevotella – 22 control, 10 PD) with ***: p ≤ 0.001 / **: p ≤ 0.01 / *: p ≤ 0.05CC BY · PubMed Central
Fig. 7 Associations of SCFAs and stool inflammatory and permeability markers with bacterial genera. Associations determined using differential expression analysis for sequence count data for full data, control subjects (n=56), and PD patients (n=55). Confounders included in confounder-corrected models were Rome III 9–15 sum score and sex. P-value is marked as follows: ***: p ≤ 0.001 / **: p ≤ 0.01 / *: p ≤ 0.05 / .: 0.1 > p > 0.05
Fig. 7 Associations of SCFAs and stool inflammatory and permeability markers with bacterial genera. Associations determined using differential expression analysis for sequence count data for full data, control subjects (n=56), and PD patients (n=55). Confounders included in confounder-corrected models were Rome III 9–15 sum score and sex. P-value is marked as follows: ***: p ≤ 0.001 / **: p ≤ 0.01 / *: p ≤ 0.05 / .: 0.1 > p > 0.05CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Aho, V. T. E., Houser, M. C., Pereira, P. A. B., Chang, J., Rudi, K., Paulin, L., Hertzberg, V., Auvinen, P., Tansey, M. G., & Scheperjans, F.
Affiliations
  • University of Helsinki (FI)
  • Emory University (US)
  • Norwegian University of Life Sciences (NO)
Corresponding author
  • Tansey, Malú G.
  • Scheperjans, Filip
ORCID
Venue
Molecular Neurodegeneration
Publisher
Springer Science and Business Media LLC
Published
2021-02-08
Volume
16
Issue
1
Pages
6-6
ISSN
1750-1326 (ISSN-L)
DOI
10.1186/s13024-021-00427-6
PMC
PMC7869249
OpenAlex
W3127379712
Cited by
435
References
56
Citations by year
2026: 58 · 2025: 96 · 2024: 93 · 2023: 86 · 2022: 81 · 2021: 20
FWCI
21.86
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Neurodegeneration (publishedVersion, cc-by)
  • medRxiv (acceptedVersion)
  • Research Square (acceptedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Työväentutkimus Vuosikirja (submittedVersion)
Funders
  • National Institute of Neurological Disorders and Stroke (1R01NS092122)
  • Michael J. Fox Foundation for Parkinson's Research (LRRK2 in immunity)
  • Academy of Finland (295724, 310835)
  • Suomen Lääketieteen Säätiö
  • Helsingin Yliopisto (UAK1014004, UAK1014005, TYH2018224)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Keywords
Parkinson's disease, gut microbiota, short-chain fatty acids, intestinal permeability, intestinal barrier, inflammation, calprotectin, zonulin, neutrophil gelatinase-associated lipocalin, interleukin-8, IL-1β, sex differences, age of onset, motor and non-motor symptoms, microbiota-host interactions
MeSH terms
Gastrointestinal Microbiome, Aged, Fatty Acids, Volatile, Female, Haptoglobins, Humans, Inflammation, Male, Middle Aged, Parkinson Disease, Protein Precursors, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review